Mydecine prepares to submit its IND and application for Breakthrough Therapy Status for smoking cessation after successful meeting with FDA.
Novamind Reports Fiscal Q2 2022 Financial Results and Operating Highlights
Novamind reports 32% q-o-q revenue growth, up to CAD $2.45 million in its latest quarter. Cash balance of ~CAD$8 million including post-period financing.
Enveric Biosciences Files Portfolio of Patent Applications for Tryptamine-Based Molecules
Enveric Biosciences announces the filing of its 10th patent application for its tryptamine-based molecules.
Gold price up as high anxiety grips marketplace
Gold and silver prices are sharply higher in early U.S. trading Monday, on safe-haven demand as the Russia-Ukraine geopolitical situation is deteriorating.
Revitalist Receives Approval from Biomedical Research Alliance of New York Permitting the Company to Perform Human Subjects Clinical Trials
Revitalist obtains regulatory approval for its clinics to host human clinical trials for psychedelics-based therapies.
Why Microdosing Cannot Replace Psychedelic Medicine
Psychedelic medicine is proving it can provide spectacular treatment results for many mental health disorders. Microdosing may also be an important therapy tool. But there's a catch.
COMPASS Pathways announces financial results for the fourth quarter and full year 2021 and business highlights
COMPASS Pathways reported its financial results for the fourth quarter and full year 2021 and gave an update on recent progress across its business.
Pasithea Therapeutics Announces Plans to Open Three New Clinics in the UK by Mid-2022
Pasiethea Therapeutics plans to offer three new clinics offering both ketamine-based and "repeated transcranial magnetic stmulation" treatments (rTMS).
Gold price moves past $1,900 as tensions mount in Ukraine
Gold prices rose above the key $1,900 an ounce level, its highest level since the end of May 2021.
Optimi Health Launches E-Commerce Platform Featuring All-Natural Functional Mushroom Supplements
Optimi Health announces the launch of six nootropic supplements derived from functional mushrooms.
Small Pharma Inc.: World’s First Clinical Trial For DMT-Assisted Therapy in Major Depressive Disorder Shows Consistent Quality of Psychedelic Response in Phase I
This analysis provides additional insight into dose-related effects on the primary outcomes of safety and tolerability.
The Future of Psychedelic Medicine: Two DIFFERENT Treatment Models
Spiritual journey or clinical therapy? What does the future of psychedelic medicine look like?
